December 27, 2005 -- As an alternative to picking individual stocks, there are four traditional, or open-ended, mutual funds that offer investors a portfolio of biotech companies, neatly packaged into a single vehicle, offering diversification. They include offerings from Fidelity, Profund, Rydex and World Funds. For some investors, it is important to have a cushion against the catastrophic loss that a failed trial can produce in a small-cap biotech company. For each one of the four, we take a look at the focus, the peculiarities and, of course, the performance...
